CS
AKCA

Credit Suisse’s Akcea Therapeutics Inc AKCA Stock Holding History

Credit Suisse’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-392,768
Closed -$7.13M – 4559
2020
Q3 		$7.13M Buy
392,768
+377,115
+2,409% +$5.35M ﹤0.01% 1560
2020
Q2 		$214K Sell
15,653
-674
-4% -$10.4K ﹤0.01% 3708
2020
Q1 		$234K Sell
16,327
-7,095
-30% -$116K ﹤0.01% 3567
2019
Q4 		$397K Buy
23,422
+11,337
+94% +$211K ﹤0.01% 3684
2019
Q3 		$186K Sell
12,085
-2,545
-17% -$54.2K ﹤0.01% 3878
2019
Q2 		$343K Sell
14,630
-12,345
-46% -$305K ﹤0.01% 3612
2019
Q1 		$764K Buy
26,975
+12,904
+92% +$376K ﹤0.01% 3093
2018
Q4 		$425K Buy
14,071
+2,230
+19% +$62.5K ﹤0.01% 3340
2018
Q3 		$415K Sell
11,841
-2,382
-17% -$72.1K ﹤0.01% 3394
2018
Q2 		$337K Sell
14,223
-12,142
-46% -$290K ﹤0.01% 3588
2018
Q1 		$676K Sell
26,365
-1,369
-5% -$29.5K ﹤0.01% 3200
2017
Q4 		$482K Buy
27,734
+17,701
+176% +$347K ﹤0.01% 3453
2017
Q3 		$277K Buy
+10,033
New +$186K ﹤0.01% 3783

Credit Suisse's AKCA Position: Q4 2020 in Review

Credit Suisse sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 392,768 shares — an estimated $7.13M sold.

Credit Suisse first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $7.13M in Q3 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Credit Suisse reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Credit Suisse sold 392,768 Akcea Therapeutics Inc shares in Q4 2020, an estimated $7.13M.
  • Credit Suisse first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • Credit Suisse's Akcea Therapeutics Inc position peaked at $7.13M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.